| Literature DB >> 32124020 |
F Wessels1, M Lenhart2, K F Kowalewski2, V Braun3, T Terboven4, F Roghmann5, M S Michel2, P Honeck2, M C Kriegmair2.
Abstract
PURPOSE: Different enhanced recovery after surgery (ERAS) protocols (EP) for radical cystectomy (RC) have been published. Protocols highly differ in number of included items and specific measures.Entities:
Keywords: Cystectomy; ERAS; Fast track; Meta-analysis; Protocol; Systematic review; evidence-based medicine
Mesh:
Year: 2020 PMID: 32124020 PMCID: PMC7716903 DOI: 10.1007/s00345-020-03133-y
Source DB: PubMed Journal: World J Urol ISSN: 0724-4983 Impact factor: 4.226
Fig. 1PRISMA flow diagram
Study characteristics and preoperative counseling
| Study | Type of study | Urinary diversion EP, | Robotic surgery EP, | Preoperative Counseling / Optimization (spec. measures) | |
|---|---|---|---|---|---|
| Altobelli et al. [ | 207/177 | Retrospective | 71/6/130/0 (34/3/63/0) | 31 (15) | Yes (not specified) |
| Baack Kukreja et al. [ | 79/121 | Prospective (ERAS only) single center non-randomized | 7/1/113/0 (6/4/90/ 0) | 44 (56) | Yes (stoma, tox cessation, comorbidities, nutrition, physical training) |
| Brockmann et al. [ | 152/147 | Prospective (ERAS only) | n.s./n.s./120/n.s (n.s./n.s./79/n.s.) | 56 (37) | No |
| Casans-Francés et al. [ | 41/97 | Retrospective | 11/0/30/0 (27/0/73/ 0) | 0 (0) | Yes (stoma, tox cessation, comorbidities, nutrition) |
| Cerruto et al. [ | 9/13 | Prospective (ERAS only) single center non-randomized | 9/0/0/0 (100/0/0/0) | 0 (0) | Yes (comorbidities, nutrition) |
| Collins et al. [ | 135/86 | Prospective (all) single center non-randomized | 38/0/97/0 (28/0/72/0) | 135 (100) | Yes (stoma, tox cessation, comorbidities, physical activity, social) |
| Djaladat et al. [ | 110/484 | Prospective (ERAS only) single center non-randomized | 105/11/53/0 (62/7/31/0) | 0 (0) | Yes (tox cessation, social) |
| Dutton et al. [ | 165 | Retrospective | 34/0/131/0 21/0/79/0 | 0 (0) | Yes (stoma, comorbidities, nutrition, physical activity, social) |
| Frees et al. [ | 10/13 | Prospective single center randomized controlled | 3/0/7/0 (30/0/70/0) | 0 (0) | Yes (not specified) |
| Jensen et al. [ | 107 | Prospective single center (RCT for factor mobilization) | 12/3/92/0 (12/2/86/0) | 25 (23) | Yes (stoma, comorbidities, nutrition, physical activity) |
| Koupparis et al. [ | 102 robotic (For MA: open 52/52)a | Prospective single center non-randomized (MA retrospective) | 11/0/91/0 (11/0/89/0) MA: 4/0/48/0 (7/0/93/0) | 102 (100) MA:0 (0)a | Yes (stoma, social) |
| Lin et al. [ | 144/145 | Prospective multicenter randomized controlled | 53/0/91/0 (37/0/63/0) | 7 (5); Laparascopic: 112 (78) | No |
| Liu et al. [ | 84 / 176 | Retrospective | 0/0/84/0 (0/0/100/0) | 0 (0) | No |
| Maffezzini et al. [ | 71/40 | Prospective (ERAS only) single center non-randomized | 23/27/31/0 (32/38/30/0) | 0 (0) | Yes (comorbidities, nutrition) |
| Mukhtar et al. [ | 51/26 | Prospective (all) single center non-randomized | 3/0/48/0 (6/0/94/0) | 0 (0) | Yes (nutrition) |
| Palumbo et al. [ | 74/40 | Prospective (all) single center non- randomized | 22/0/24/25 (30/0/33/34) | 0 (0) | No |
| Pang et al. [ | 393/60 | Prospective (all) single center non-randomized | 25/0/368/0 (6/0/94/ 0) | 28 (7) | Yes (stoma, tox cessation, comorbidities, physical activity) |
| Patel et al. [ | 116/143 | Retrospective, comparison surgical vs. multidisc. ERAS | 19/5/92/0 16/4/79/ 0 | 0 (0) | No |
| Persson et al. [ | 31/39 | Prospective (all) single center non-randomized | 5/0/26/0 (17/0/83/0) | 0 (0) | Yes (not specified) |
| Rivas et al. [ | 19/28 | Retrospective | 4/0/15/0 (21/0/79/0) | Laparascopic: 19 (100) | Yes (not specified) |
| Saar et al. [ | 31/31 | Prospective (all) single center non-randomized | 8/0/23/0 (26/0/74/0) | 31 (100) | No |
| Semerjian et al. [ | 56/54 | Prospective (ERAS only) single center non-randomized | 3/0/53/0 (5/0/95/0) | 8 (14) | Yes (not specified) |
| Smith et al. [ | 27/69 | Retrospective | 0/0/27/0 (0/0/100/0) | 0 (0) | Yes (stoma, nutrition) |
| Tan et al. [ | 40/210 | Prospective (all) single center non-randomized | 11/0/39/0 (22/0/78/0) | 40 (100) | Yes (stoma, comorbidities) |
| Wei et al. [ | 91/101 | Retrospective | 3/0/82/6 (3/0/90/7) | 0 (0) | Yes (tox cessation, nutrition) |
MA meta−analysis
aNon ERAS−patients underwent only open cystectomies therefore MA was performed open non ERAS vs open ERAS not including robotic patients for better comparability
Bowel management
| Study | Preoperative bowel preparation (BP) | Prevention of ileus | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oral | i.v | Rectal | ||||||||||
| Oral BP | Rectal BP | Carbohydrate loading | No NGT postop | Gum chewing | Mg2+ | Alvimopan | Others | MCP | Neostigmin | Others | enema | |
| Altobelli et al. [ | − | − | − | − | − | − | + | − | − | − | − | − |
| Baack Kukreja et al. [ | − | − | + | + | + | − | + | + | + | ( +) | − | ( +) |
| Brockman et al. [ | − | − | − | + | − | − | + | − | − | − | − | − |
| Casans-Francés et al. [ | − | − | + | + | + | − | − | + (Lactulose) | + | − | − | − |
| Cerruto et al. [ | − | + | + | + | + | − | − | − | + | − | − | ( +) |
| Collins et al. [ | − | − | + | + | + | − | − | − | + | − | − | − |
| Djaladat et al. [ | − | − | + | + | − | + | + | + (Lactulose) | ( +) | + | − | − |
| Dutton et al. [ | − | − | + | + | − | − | − | − | + | − | − | − |
| Frees et al. [ | − | − | + | + | + | − | − | − | + | − | − | − |
| Jensen et al. [ | − | + | + | n.s | − | − | − | n.s | − | − | n.s | − |
| Koupparis et al. [ | − | − | + | + | + | − | − | − | + | − | − | − |
| Lin et al. [ | + (Laxative) | − | − | + | − | − | − | − | − | − | + | ( +) |
| Liu et al. [ | − | − | + | + | + | + | − | − | − | − | − | − |
| Maffezzini et al. [ | − | + | − | − | − | − | − | − | − | − | ( +) | − |
| Mukhtar et al. [ | − | − | + | + | − | − | − | − | − | − | − | − |
| Palumbo et al. [ | − | + | + | + | − | − | − | − | − | − | − | − |
| Pang et al. [ | − | − | + | + | + | − | − | − | − | − | − | ( +) |
| Patel et al. [ | − | − | − | + | − | + | − | − | − | − | − | |
| Persson et al. [ | − | − | + | + | − | − | − | + (Laxative) | − | − | − | − |
| Rivas et al. [ | − | + | − | + | + | − | − | − | + | − | − | − |
| Saar et al. [ | − | + | + | + | − | + | − | − | + | − | − | + |
| Semerjian et al. [ | − | − | + | + | − | − | + | − | − | − | − | − |
| Smith et al. [ | − | − | + | + | + | + | − | − | − | − | + | − |
| Tan et al. [ | − | − | + | + | + | + | − | − | + | − | − | − |
| Wei et al. [ | − | − | − | + | + | − | − | − | − | − | − | − |
+ regularly used, (+) used depending on clinical outcome, − not used, n.s. not stated, MCP metoclopramide
Anesthesia and pain management
| Study | No | Anesthesia | Pain management | |||||
|---|---|---|---|---|---|---|---|---|
| Antibiotic duration | Avoid long acting sedative | Optimized fluid management | Prevention of PONV | Epidural | Regional Infiltration | Non-epidural pain medication | ||
| Altobelli et al. [ | 207 | 24 h | + | + | n.s | + | - | n.s |
| Baack Kukreja et al. [ | 79 | 24 h | n.s | + | n.s | + (open) | + (lap) | NSAI + paracetamol ± weak opioids ± narcotics |
| Brockman et al. [ | 152 | SD | n.s | + | n.s | + | − | n.s |
| Casans-Francés et al. [ | 41 | SD | + | + (Protocol by Feldheiser et al. [ | + (Apfel scale) | + | – | NSAI |
| Cerruto et al. [ | 9 | SD | + | + | + | + | + | NSAI |
| Collins et al. [ | 135 | SD | + (spinal) | + | n.s | − | − | NSAI + opioid |
| Djaladat et al. [ | 196 | stent removal | + | + | n.s | − | − | NSAI + Paracetamol |
| Dutton et al. [ | 165 | SD | n.s | + | n.s | − | + (RSC) | NSAI + weak opioid |
| Frees et al. [ | 12 | n.s | n.s | + (Doppler monitoring) | n.s | + | − | NSAI ± opioid |
| Jensen et al. [ | 57 | SD | n.s | n.s | n.s | − | − | NSAI ± opioid |
| Koupparis et al. [ | 102 | n.s | n.s | + | + | + | − | Paracetamol + opioid |
| Lin et al. [ | 144 | SD | n.s | n.s | n.s | − | − | n.s |
| Liu et al. [ | 84 | SD | + | + | + | + | − | n.s |
| Maffezzini et al. [ | 71 | drain removal | n.s | + | n.s | + | − | n.s |
| Mukhtar et al. [ | 51 | n.s | + | + | + | + | − | non-opioid |
| Palumbo et al. [ | 74 | POD 4 | + | + (Ringer’s acetate solution 1–2 mg/kg/h) | n.s | − | − | Paracetamol + diclofenac ± weak opioid |
| Pang et al. [ | 393 | 24 h (m) 48 h (f) | + | + (< 1L before bladder removal, use of vasopressors) | + | − | + (RSC) | Paracetamol |
| Patel et al. [ | 116 | n.s | n.s | + (minimally invasive volume monitor) | n.s | + | − | Paracetamol |
| Persson et al. [ | 31 | SD | + | + | + | + | − | n.s |
| Rivas et al. [ | 19 | SD | + | + | n.s | + | − | Avoid opioid |
| Saar et al. [ | 31 | SD | - | - | − | − | − | diclofenac + NSAI ± opioids |
| Semerjian et al. [ | 56 | 24 h | + | + (125-200 ml Ringer/h ± bolus depending on losses, phenylephrine) | + | + (open) | + (Robotic: TAP-Block) | Paracetamol + gabapentin + tranSDermal lidocaine ± weak opioid ± opioid |
| Smith et al. [ | 27 | n.s | n.s | + (esophageal doppler) | n.s | − | + (RSC) | n.s |
| Tan et al. [ | 40 | n.s | + (spinal) | + (esophageal doppler) | n.s | − | − | NSAI + Paracetamol ± opioid |
| Wei et al. [ | 91 | n.s | n.s | + (vascular pressure) | n.s | + | + (RSC) | intravenous opioid on demand |
+ used, − not used, n.s. not specified, SD single dose, RSC rectus sheath catheter, TAP transversus abdominis plane block
Fig. 2Meta-analysis of perioperative outcome
Quality assessment of included studies
| Non-randomized Study | Type | Selection | Comparability | Outcome | |||||
|---|---|---|---|---|---|---|---|---|---|
| Retrospective / Prospective / RCT | Representativeness of the exposed cohort | Selection of the non-exposed cohort | Ascertainment of exposure | Demonstration that outcome of interest was not present at start of study | Comparability of cohorts on the basis of the design or analysis | Assessment of outcome | Was follow-up long enough for outcomes to occur | Adequacy of follow up of cohorts | |
| Altobelli et al. [ | retrospective | ||||||||
| Arumainayagam et al. [ | retrospective | ||||||||
| Baack Kukreja et al. [ | ERAS prospective | ||||||||
| Brockman et al. [ | ERAS prospective | ||||||||
| Casans-Francés et al. [ | retrospective | ||||||||
| Cerruto et al. 2014 [ | ERAS prospective | ||||||||
| Collins et al. [ | Prospective | ||||||||
| Djaladat et al. [ | ERAS prospective | ||||||||
| Liu et al. [ | retrospective | ||||||||
| Maffezzini et al. [ | ERAS prospective | ||||||||
| Mukhtar et al. [ | Prospective | ||||||||
| Palumbo et al. [ | Prospective | ||||||||
| Pang et al. [ | Prospective | ||||||||
| Persson et al. [ | Prospective | ||||||||
| Rivas et al. [ | Retrospective | ||||||||
| Saar et al. [ | Prospective | ||||||||
| Semerjian et al. [ | ERAS Prospective | ||||||||
| Smith et al. [ | Retrospecitve | ||||||||
| Tan et al. [ | Prospective | ||||||||
| Wei et al. 2018 [ | Retrospective | ||||||||
RoB risk of bias
This table shows a quality assessment for non-randomized and randomized studies. For non-randomized studies Newcastle Ottawa scale was used. Here, stars show achievement of a specific quality assessment. For clarification, please place the following amend beneath the table: “Quality assessment of non-randomized studies was done by using Newcastle Ottawa Quality Assessment for cohort studies. For Selection a maximum of four stars could be awarded. For a star in Representativeness the ERAS and non-ERAS groups had to consist of consecutive patients with urothelial cancer undergoing radical cystectomy. For Selection, patients had to be operated in the same institution. For Ascertainment of exposure perioperative outcomes had to be extracted from surgical and patient records. For Demonstration that outcome of interest was not present at start all studies were awarded with one point as perioperative outcome such as complication rate were the main outcomes.
For Comparability, two stars could be awarded. One star was given for type of radical cystectomy. If there was a significant difference in open, robotic or laparoscopic technique or in type of urinary diversion, no star was awarded. For the second star, groups had to be similar in BMI, comorbidities (measured in CCI, ASA-Score, or other similar score), T-Stage of urothelial cancer and age to be awarded with a star. For Outcome, Assessment of outcome had to be blind or assessed by patient, surgical or database records to be awarded with a star. For length of Follow-up, a length of 90days was considered adequate. A follow up above 90% was considered necessary due to the short time of necessary length of follow-up
Summary of findings
| Summary of findings |
|---|
CI confidence interval, OR odds ratio
Explanations
a*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)
aInclusion of non-randomized studies
bHigh I2
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect